A Randomized Phase II Trial of Erlotinib Alone or In Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2017 Planned number of patients changed from 86 to 112.
- 11 Oct 2017 Planned primary completion date changed from 1 Mar 2018 to 16 Mar 2018.
- 10 Jun 2017 Biomarkers information updated